Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia

First-line durvalumab plus tremelimumab safe to use in unresectable HCC
05 Sep 2025
bởiStephen Padilla
The phase IIIb SIERRA study has shown an acceptable safety profile for the single tremelimumab regular interval durvalumab (STRIDE) regimen as first-line treatment for patients with hepatocellular carcinoma (HCC) who have a poor prognosis.







